CARIS LIFE SCIENCES, INC.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2022 | — | $-1.70B | — |
| FY2023 | — | $-2.14B | — |
| FY2024 | $319.4M | $-2.50B | $64.0M |
| FY2025 | $378.8M | $577.3M | $796.3M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2022 | — | $-1.70B | — |
| FY2023 | — | $-2.14B | — |
| FY2024 | $319.4M | $-2.50B | $64.0M |
| FY2025 | $378.8M | $577.3M | $796.3M |